Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NET Clear all
Completed Phase 4 Interventional Results available

Bridging the Evidence-to-practice Gap

NCT03713515
View directory record Official record
Conditions
Hypertension
Interventions
ALTA
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

NCT02784535
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening

NCT03414125
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FIT Screening Strategy, Choice Screening Strategy
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 63 Years
Enrollment
26,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 25, 2026, 6:53 PM EDT
Active, not recruiting Phase 1 Interventional

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

NCT04609592
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NET-Works:Community Preschooler Obesity Prevention

NCT01606891
View directory record Official record
Conditions
Childhood Obesity
Interventions
multi-component/setting parent-targeted intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
2 Years to 4 Years
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

NCT00510068
View directory record Official record
Conditions
Advanced Neuroendocrine Tumors of Pancreatic Origin
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
24
States / cities
Mobile, Alabama • Anaheim, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 25, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Surufatinib in European Patients With NET

NCT04579679
View directory record Official record
Conditions
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
Interventions
Surufatinib
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Orange, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

NCT05579574
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evidence Based Dissemination for Mammography Adherence in Safety Net Communities

NCT02296177
View directory record Official record
Conditions
Breast Cancer
Interventions
Peace of Mind Program
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older · Female only
Enrollment
4,448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Tobacco Use Disparities Among Low-Income Adults

NCT03077737
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
Choose to Change, Enhanced usual care
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 25, 2026, 6:53 PM EDT
Terminated No phase listed Observational

Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates

NCT01735552
View directory record Official record
Conditions
Anemia of Prematurity, Necrotizing Enterocolitis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 12 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Group-based Integrative Pain Management (IPMP+ Pilot)

NCT05906784
View directory record Official record
Conditions
Chronic Pain
Interventions
group acupuncture, Integrative Group Medical Visits
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 25, 2026, 6:53 PM EDT
Active, not recruiting Early Phase 1 Interventional

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

NCT06148636
View directory record Official record
Conditions
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
Interventions
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
Drug · Diagnostic Test
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 25, 2026, 6:53 PM EDT
Completed No phase listed Observational

Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant

NCT01735565
View directory record Official record
Conditions
Bone Marrow Transplant
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Heart Failure Polypill at a Safety Net Hospital

NCT06029712
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, HIV Infections
Interventions
Heart failure polypill, Control Rx
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 25, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Telotristat With Lutathera in Neuroendocrine Tumors

NCT04543955
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Telotristat (Low-Dose), Telotristat (High-Dose)
Drug
Lead sponsor
Lowell Anthony, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 25, 2026, 6:53 PM EDT
Withdrawn Phase 2 Interventional

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

NCT01048086
View directory record Official record
Conditions
Neuroblastoma, Neuroendocrine Tumor
Interventions
Retinoic Acid, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
6 Months to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 25, 2026, 6:53 PM EDT
Enrolling by invitation Phase 3 Interventional

Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

NCT07637162
View directory record Official record
Conditions
Fibromyalgia
Interventions
AXS-14 (esreboxetine)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
35
States / cities
Little Rock, Arkansas • Oceanside, California • Redlands, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 6:53 PM EDT
Active, not recruiting Not applicable Interventional

Transitioning Together Boston

NCT05599711
View directory record Official record
Conditions
Autism or Autistic Traits, Family Relations
Interventions
Transitioning Together (TT) / Juntos en la Transicion (JET), Usual autism transition care
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
14 Years to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 25, 2026, 6:53 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752
View directory record Official record
Conditions
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATE, Octreotide LAR
Radiation · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
20
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 6:53 PM EDT
Not listed No phase listed Observational

"Assessment of Risk Factors for Depression Treatment at a Safety Net Clinic"

NCT00984685
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Scranton-Temple Residency Program
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

NCT00774930
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Lanreotide, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 25, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Neural-net Artificial Pancreas (NAP)

NCT05876273
View directory record Official record
Conditions
Type1 Diabetes
Interventions
Neural-net Artificial Pancreas, University of Virginia Model Predictive Control
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 25, 2026, 6:53 PM EDT
Active, not recruiting Not applicable Interventional

Multi-ethnic Multi-level Strategies and Behavioral Economics to Eliminate Hypertension Disparities in Los Angeles County

NCT06359691
View directory record Official record
Conditions
Hypertension
Interventions
Patient-focused strategies, Provider-focused strategies, Patient- and provider-focused strategies
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 25, 2026, 6:53 PM EDT